Milestone Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. The company's lead product is CARDAMYST (etripamil) nasal spray, a novel rapid-onset calcium channel blocker. In December 2025, the U.S. FDA approved CARDAMYST for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This landmark approval transitioned Milestone from a development-stage biotechnology firm into a commercial-stage specialty pharmaceutical operator. CARDAMYST represents the first FDA-approved, patient-administered therapy for acute PSVT in over three decades, shifting the treatment paradigm from costly emergency department interventions to patient self-administration in medically unsupervised settings. Beyond PSVT, Milestone is actively developing etripamil for other episodic cardiovascular conditions, notably initiating a Phase 3 registrational program for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing the commercial rollout of CARDAMYST (etripamil) nasal spray in U.S. retail pharmacies, supported by a dedicated cardiology-focused sales force and securing broad payer coverage.
Expected impact: Establishment of the company's first recurring product revenue stream and market penetration among the estimated 500k–800k potential PSVT users in the U.S.
Advancing etripamil into a Phase 3 registrational program (ReVeRa-301 study) for patients experiencing symptomatic episodic attacks associated with atrial fibrillation and rapid ventricular rate (AFib-RVR).
Expected impact: Potential to expand the addressable market significantly beyond the initial PSVT indication.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Everest Medicines acquired the Greater China rights for CARDAMYST from Corxel Pharmaceuticals (Milestone's original partner) in March 2026, taking over development, manufacturing, and commercialization in Mainland China, Hong Kong, Macao, and Taiwan.
Terms: Milestone remains eligible for regulatory and sales milestone payments, as well as tiered royalties on net sales in the licensed territory.
Provides non-dilutive capital to fund operations, clinical trials, and commercial launch activities without immediate equity dilution.
Terms: RTW provided a $75 million payment upon FDA approval of CARDAMYST in exchange for a tiered royalty interest on annual net product sales of CARDAMYST in the United States.